Abstract
The term retinitis pigmentosa (RP) indicates a heterogeneous group of genetic rare ocular diseases in which either rods or cones are prevalently damaged. RP represents the most common hereditary cause of blindness in people from 20 to 60 years old. In general, the different RP forms consist of progressive photo-receptorial neuro-degenerations, which are characterized by variable visual disabilities and considerable socio-sanitary burden. Sometimes, RP patients do not become visually impaired or legally blind until their 40-50 years of age and/or maintain a quite acceptable sight for all their life. Other individuals with RP become completely blind very early or in middle childhood. Although there is no treatment that can effectively cure RP, in some case-series the disease's progression seems to be reducible by specific preventive approaches. In the most part of RP patients, the quality of vision can be considerably increased by means of nanometer-controlled filters. In the present review, the main aspects of the routine clinical and rehabilitative managements for RP patients are described, particularly focusing on the importance of specific referral Centers to practice a real multidisciplinary governance of these dramatic diseases.
Keywords: glaucoma, photophobia, neurodegeneration, rehabilitation, herapy, prevention, clinical governance, multidisciplinary management, retinitis pigmentosa, Inherited retinal dystrophies
Current Genomics
Title: Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date
Volume: 12 Issue: 4
Author(s): Katia De Nadai, Mario R. Romano, Andrea Binotto, Ciro Costagliola, Giovanni Sato and Francesco Parmeggiani
Affiliation:
Keywords: glaucoma, photophobia, neurodegeneration, rehabilitation, herapy, prevention, clinical governance, multidisciplinary management, retinitis pigmentosa, Inherited retinal dystrophies
Abstract: The term retinitis pigmentosa (RP) indicates a heterogeneous group of genetic rare ocular diseases in which either rods or cones are prevalently damaged. RP represents the most common hereditary cause of blindness in people from 20 to 60 years old. In general, the different RP forms consist of progressive photo-receptorial neuro-degenerations, which are characterized by variable visual disabilities and considerable socio-sanitary burden. Sometimes, RP patients do not become visually impaired or legally blind until their 40-50 years of age and/or maintain a quite acceptable sight for all their life. Other individuals with RP become completely blind very early or in middle childhood. Although there is no treatment that can effectively cure RP, in some case-series the disease's progression seems to be reducible by specific preventive approaches. In the most part of RP patients, the quality of vision can be considerably increased by means of nanometer-controlled filters. In the present review, the main aspects of the routine clinical and rehabilitative managements for RP patients are described, particularly focusing on the importance of specific referral Centers to practice a real multidisciplinary governance of these dramatic diseases.
Export Options
About this article
Cite this article as:
De Nadai Katia, R. Romano Mario, Binotto Andrea, Costagliola Ciro, Sato Giovanni and Parmeggiani Francesco, Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date, Current Genomics 2011; 12 (4) . https://dx.doi.org/10.2174/138920211795860125
DOI https://dx.doi.org/10.2174/138920211795860125 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer’s Disease
Current Alzheimer Research A Critical Evaluation of Adenosine A2A Receptors as Potentially “Druggable” Targets in Huntingtons Disease
Current Pharmaceutical Design In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Current Opinions and Perspectives on the Role of Immune System in the Pathogenesis of Parkinson's Disease
Current Pharmaceutical Design Lentiviral Vectors: A Powerful Tool to Target Astrocytes In Vivo
Current Drug Targets β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry Editorial [Hot topic: Inhibition and Function of Heat Shock Proteins 70 and 90 (Guest Editor: Brian S. J. Blagg)]
Current Topics in Medicinal Chemistry Autophagy in Invertebrates: Insights Into Development, Regeneration and Body Remodeling
Current Pharmaceutical Design Patent Selections
Recent Patents on Biotechnology Golgi Localization of Glycosyltransferases Involved in Ganglioside Biosynthesis
Current Drug Targets Editorial: Alzheimer's Disease: From Molecular Mechanisms to Psychobiological Perspectives
Current Alzheimer Research Vitamin E - Occurrence, Biosynthesis by Plants and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Experimental and Clinical Advances in Immunotherapy Strategies for Spinal Cord Injury Target on MAIs and Their Receptors
Current Pharmaceutical Design Hippocampal BDNF Expression in a Tau Transgenic Mouse Model
Current Alzheimer Research Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry Lipid-based Nano-phytomedicines for Disease Treatment and Theranostic Applications
Current Nanomedicine Astroglial Connexins in Neurological and Neuropsychological Disorders and Radiation Exposure
Current Medicinal Chemistry Excitotoxicity as a Target Against Neurodegenerative Processes
Current Pharmaceutical Design